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Abstract
Introduction Genetic variations may influence clinical outcomes
in patients with sepsis. The present study was conducted to
evaluate the impact on mortality of three polymorphisms after
adjusting for confounding variables, and to assess the factors
involved in progression of the inflammatory response in septic
patients.
Method The inception cohort study included all Caucasian
adults admitted to the hospital with sepsis. Sepsis severity,
microbiological information and clinical variables were recorded.
Three polymorphisms were identified in all patients by PCR: the
tumour necrosis factor (TNF)-α 308 promoter polymorphism;
the polymorphism in the first intron of the TNF-β gene; and the
IL-10-1082 promoter polymorphism. Patients included in the
study were followed up for 90 days after hospital admission.
Results A group of 224 patients was enrolled in the present
study. We did not find a significant association among any of the
three polymorphisms and mortality or worsening inflammatory
response. By multivariate logistic regression analysis, only two
factors were independently associated with mortality, namely
Acute Physiology and Chronic Health Evaluation (APACHE) II
score and delayed initiation of adequate antibiotic therapy. In
septic shock patients (n  = 114), the delay in initiation of
adequate antibiotic therapy was the only independent predictor
of mortality. Risk factors for impairment in inflammatory
response were APACHE II score, positive blood culture and
delayed initiation of adequate antibiotic therapy.
Conclusion This study emphasizes that prompt and adequate
antibiotic therapy is the cornerstone of therapy in sepsis. The
three polymorphisms evaluated in the present study appear not
to influence the outcome of patients admitted to the hospital
with sepsis.
Introduction
Mortality from sepsis remains unacceptably high despite
recent advances in diagnostic procedures, antimicrobial treat-
ment, and supportive care [1,2]. Although antibiotic therapy is
the cornerstone of treatment of infections, the influence of
adequate antimicrobial therapy on prognosis in septic patients
was not clearly proven until recently. We and others demon-
strated that after controlling for confounding variables, ade-
quate empirical antibiotic treatment is associated with
reduced mortality in critically ill septic patients [3-5]. Interest-
ingly, the impact on outcome of delayed adequate antibiotic
therapy has not been studied in septic patients. The variables
that can influence outcome in septic patients are numerous
(such as, age, underlying disease, source of sepsis, presence
of bacteraemia and organ system dysfunction). In addition,
several interventions have been shown to decrease mortality in
sepsis and should be taken into account when analyzing the
impact on outcome of any single factor.
APACHE = Acute Physiology and Chronic Health Evaluation; bp = base pair; CI = confidence interval; ICU = intensive care unit; IL = interleukin; OR 
= odds ratio; PCR = polymerase chain reaction; SOFA = Sequential Organ Failure Assessment; TNF = tumour necrosis factor.Critical Care    Vol 10 No 4    Garnacho-Montero et al.
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At the beginning of the third millennium, much interest and
great expectation were focused on advances in molecular biol-
ogy, and particularly on the completion of Human Genome
Project. Individual variants of genes encoding mediators that
are involved in the inflammatory response to an infectious
agent might account for differences in clinical evolution and
outcome of septic patients treated correctly and with appar-
ently similar approaches. Tumour necrosis factor (TNF) is con-
sidered the most important proinflammatory cytokine,
recruiting and activating immune cells, stimulating the release
of other proinflammatory mediators and regulating apoptosis.
In contrast, IL-10 is the paradigmatic anti-inflammatory
cytokine. It exerts its biological properties by inhibiting the
release of proinflammatory cytokines and preventing apopto-
sis. However, contradictory observations have been reported
on the impact on outcome of polymorphisms in these
cytokines that are directly responsible for the host response
[6,7].
An international panel of experts defined systemic inflamma-
tory response syndrome, sepsis, severe sepsis and septic
shock, which are viewed as a continuum of risk [8]. Factors
that influence the progression of inflammatory response in
patients admitted to the hospital because of sepsis have not
been elucidated. In other words, the causes why clinical situa-
tion deteriorates are not clearly known.
Hence, the primary aim of the present study, conducted in
adults admitted to the hospital with sepsis, was to evaluate the
impact on in-hospital mortality (and 90-day mortality) of three
polymorphisms (the TNF-α-308 promoter polymorphism, the
polymorphism in the first intron of the TNF-β gene, and the IL-
10-1082 promoter polymorphism), after controlling for various
confounding variables including delayed adequate antibiotic
therapy. We chose these mediators because an altered bal-
ance in their serum concentrations has been associated with
poor outcome in patients with community-acquired infection
[9], and we selected these specific polymorphisms because of
their functional significance [10-12]. Our secondary objec-
tives were to explore this same objective in patients with septic
shock and to assess the factors that are involved in progres-
sion of the inflammatory response.
Materials and methods
Hospital
This prospective study was carried out in the Hospital Virgen
del Rocío – a large university hospital with a 40-bed intensive
care unit (ICU) – from June 2002 to December 2004. Written
informed consent was obtained from patients or their relatives,
and the ethics committee of the hospital approved the study.
Patients
Eligible patients were Caucasian adults (age >18 years) who
arrived in at the emergency department meeting criteria for
sepsis. Infected patients who did not fulfill sepsis criteria were
not included. The criteria followed for ICU admission were
based on the patient clinical condition, being shock or respira-
tory insufficiency the main reasons for ICU admission. Patients
not admitted to the ICU were transferred to the general ward.
The exclusion criteria were neutropenia (white blood cell count
<500/µl), positive HIV serologic results and pregnancy.
Patients included in the protocol were followed up until death
or hospital discharge. Vital status of those patients discharged
from the hospital before 90 days was ascertained by search-
ing in the hospital database or telephone contact. The control
group comprised 101 healthy unrelated blood donors from the
hospital blood bank.
Study design
All patients diagnosed with sepsis received standard support-
ive treatment, including prompt fluid resuscitation, vasoactive
drugs and empirical antimicrobial therapy, which was chosen
by the attending physician [3]. Intravenous hydrocortisone
(200 mg/day for seven days) was used in patients in septic
shock who, despite fluid replacement, required vasopressor
agents [13], and continuous infusion of insulin was adminis-
tered to control blood glucose levels, in accordance with the
results of a large clinical trial [14]. All patients on mechanical
ventilation were managed following ARDSNet recommenda-
tions [15].
All patients had a series of blood cultures drawn at admission.
Sepsis was documented when a relevant micro-organism from
a suspected focus was isolated and/or bacteraemia was
present. Cultures of infection sources were obtained in all
patients as clinically indicated. Paired serum samples were
tested for evidence of antibody against respiratory viruses,
Legionella pneumophila,  Chlamydia  spp.,  Coxiella burnetii
and Mycoplasma pneumoniae. Tracheal aspirate or protected
brush specimen were obtained from all patients with commu-
nity-acquired pneumonia who required mechanical ventilation.
Variables
Sepsis, severe sepsis and septic shock were defined follow-
ing current definitions [8]. Severity of illness was evaluated
using the Acute Physiology and Chronic Health Evaluation
(APACHE) II score, recording the worst reading during the
first 24 hours in the hospital [16]. Chronic organ insufficien-
cies (liver, renal, pulmonary, cardiovascular and immunosup-
pression) were recorded as defined in the APACHE II scale,
and other comorbidities (alcoholism, smoking habit, diabetes
mellitus and noncured malignancy) as defined by Pittet and
coworkers [17]. Other variables recorded included bacterae-
mia, microbiologically documented infection and delay from
hospital admission (documented time when the patient arrived
at the emergency department) to administration of adequate
antibiotic therapy. Time elapsed from hospital admission to
onset of operation was noted in surgical patients. Empirical
therapy was considered adequate when at least one effective
drug was included in the antibiotic treatment regimen withinAvailable online http://ccforum.com/content/10/4/R111
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the first 24 hours in the hospital, and the dose and pattern of
administration were in accordance with current standards.
Failure of organs was evaluated using the Sequential Organ
Failure Assessment (SOFA) scale on admission and during
the subsequent clinical course [18]. Worsening in the inflam-
matory response was monitored by two methods: we deter-
mined the proportion of patients admitted to the hospital with
sepsis who developed severe sepsis or septic shock and the
proportion of patients with severe sepsis at admission who
developed septic shock; and we calculated the delta-SOFA
(i.e. the worst SOFA score during hospitalization minus the
SOFA score during the first 24 hours) [19]. Nosocomial infec-
tions (pneumonia, catheter-related bloodstream infection and
primary bacteraemia) were diagnosed as previously defined
[20].
Genotyping
Genomic DNA from each patient was extracted from whole
blood using a DNA extraction Kit (Puregene DNA Isolation kit,
Minneapolis, MN, USA), in accordance with the manufac-
turer's instructions.
Polymorphism at TNF-α promoter position -308
DNA samples were amplified by PCR with forward primer
TNF-α-F (5'-AGG CAA TAG GTT TTG AGG GCC AT-3') and
reverse primer TNF-α-R (5'-ACA CTC CCC ATC CTC CCT
GCT-3'). The TNF-α primer includes a single base pair (bp)
mismatch, which introduces an NcoI restriction site after
amplification when the G allele is present at position -308. A
116 bp PCR product was obtained from a 50 µl reaction mix
containing 100 ng DNA, 1 µmol/l each primer, 0.2 mmol/l
dNTP, 1× buffer, 1.5 mmol/l MgCl2 and 1 U Taq polymerase
(Finnzymes, Espoo, Finland). The reaction was carried out with
the following cycles: 95°C for 2 minutes; 35 cycles of 95°C for
30 s, 60°C for 15 s and 74°C for 15 s; and 74°C for 10 min-
utes for final extension. The PCR product was incubated with
NcoI (New England Biolabs) and digested, and undigested
samples were visualized by electrophoresis in 4% Nu Sieve
agarose gel (Master Diagnostica, Madrid, Spain) and ethidium
bromide staining. A single band at 116 bp identified AA
homozygous individuals, two bands at 96 and 20 bp identified
GG homozygous individuals, and three bands at 116, 96 and
20 bp indicated a heterozygote at the TNF-α-308 locus.
Polymorphism in the first intron of the TNF-β gene (NcoI 
polymorphism)
The region with the +250 polymorphism, which contains an
NcoI restriction site when the G allele is present, was amplified
using primers TNF-β-F (5'-CCG TGC TTC GTG CTT TGG
ACT A-3') and TNF-β-R (5'-AGA GGG GTG GAT GCT TGG
GTT C-3'). Each 50 µl reaction mix consisted of 100 ng DNA,
1 µmol/l each primer, 0.2 mmol/l dNTP, 1× buffer, 1.5 mmol/l
MgCl2 and 1 U Taq polymerase. Amplification was performed
with an initial denaturation of 95°C for 2 minutes; followed by
35 cycles of 94°C for 30 s, 69°C for 30 s and 74°C for 42 s;
and completing the reaction with a final extension step of 74°C
for 10 minutes. The 782 bp PCR product was digested with
the restriction enzyme NcoI (New England Biolabs), incubat-
ing at 37°C for two hours. The obtained fragments as well as
undigested samples were analyzed by electrophoresis in
1.5% agarose gel and visualized by ethidium bromide staining.
The presence of a single band of 782 bp identified individuals
who were AA homozygous, two bands at 586 and 196 bp indi-
cated those who were GG homozygous, and heterozygous
individuals were identified by three bands at 782, 586 and
196 bp.
Polymorphism at IL-10 promoter position -1082
IL-10-1082 polymorphism results from the substitution of gua-
nine with adenine, which abolishes a MnlI restriction site. The
region containing this polymorphism was amplified by PCR
using primers IL-10-F (5'-CTC GTC GCA ACC CAA CTG-3')
and IL-10-R (5'-ACT TTC ATC TTA CCT ATC CCT ACT TCC-
3'). The amplified region also includes the CA repeat micros-
atellites located at -1151 (IL-10-G polymorphism). A 50 µl
reaction mix contained 100 ng DNA, 0.5 µmol/l each primer,
0.2 mmol/l dNTP, 1× buffer, 1.5 mmol/l MgCl2 and 1 U Taq
polymerase. The PCR conditions used were as follows: a
denaturing step of 94°C for 3 minutes and then 35 cycles of
94°C for 15 s, 60°C for 15 s and 72°C for 30 s, with a final
extension at 72°C for five minutes. The PCR product was ana-
lyzed by electrophoresis in 4% Nu Sieve agarose gel (Master
Diagnostica) and visualized by ethidium bromide staining. An
undigested single band at 139 bp (when 20 CA repeats are
present) identified individuals who were AA homozygous, two
bands at 101 and 38 bp identified those who were GG
homozygous, and three bands at 139, 101 and 38 bp indi-
cated a heterozygote at the -1082 locus.
Statistical analysis
The main outcome measure was in-hospital mortality from any
cause, but we also assessed 90-day mortality. Sample size
was calculated considering a difference of 10% in hospital
mortality between groups as relevant, the frequency of the alle-
les in the population (control group), and a β error of 20% and
an α error of 5%. An interim analysis was planned after 225
patients were enrolled. At that point, the absolute difference in
mortality between AA individuals of TNF-β (the polymorphisms
more consistently associated with mortality) and GG/GA indi-
viduals was only 5%, and this was considered not clinically rel-
evant in septic patients, whose outcome is influenced by many
variables. With these data, it would be required to enroll 2,500
patients to achieve statistical significance. For these reasons,
we elected to terminate the study.
Descriptive results of continuous variables are expressed as
median (25th and 75th percentiles). The association between
risk factors and death was first examined by means of bivariate
analysis. This was accomplished using two-sample unpaired t-Critical Care    Vol 10 No 4    Garnacho-Montero et al.
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test for continuous variables after correction for equality of var-
iance (Levene's test), χ2 test, or Fisher's exact test for categor-
ical variables. Relative risks and their corresponding 95%
confidence intervals (CIs) were calculated. P < 0.05 was con-
sidered to reflect statistical significance.
A stratified analysis was performed before the multivariate
analysis using the Mantel-Hanszel χ2 test, in order to evaluate
the presence of interactions and confounding factors among
variables. A multivariate analysis using logistic regression anal-
ysis was used to determine variables independently associ-
ated with mortality in the entire group and only in those
patients who fulfilled septic shock criteria. The model was con-
structed using a forward stepwise method with the likelihood
ratio test. The variables tested for inclusion in the model had
an entry level P < 0.10 in the univariate analysis, but only those
with P < 0.05 are reported. The odds ratios (ORs) and their
corresponding 95% CI for each variable were also calculated
[21]. Moreover, in order to assess the associations among
quantitative variables with delayed initiation of adequate anti-
biotic therapy, a multiple linear regression analysis was per-
formed.
Results
A total of 293 patients were screened for inclusion in the
study, although 69 were excluded from the final analysis.
Therefore, only 224 patients were evaluable. The causes of
exclusion are listed in Table 1. Forty-six patients were hospital-
ized in the general ward and 178 patients were admitted to the
ICU (four of them were initially transferred to the general
ward). Fifty-two patients died in the hospital (23.2%), whereas
in-hospital mortality of the 69 excluded patients was 21.7% (P
> 0.05). The demographic data and the distribution of geno-
types of the 224 patients and 101 control individuals are sum-
marized in Table 2. The distribution of genotypes for the
analyzed polymorphisms did not differ between patients with
sepsis and control individuals.
At admission to the hospital, a clinical picture of sepsis was
present in 78 cases (34.8%), severe sepsis in 85 (38%) and
Table 1
Reasons for exclusion of 69 patients screened in the present 
study
Reason Number
Permission denied 20
Diagnosis other than sepsis 20
Race other than Caucasian 13
Do not resuscitate order 8
Technical problem to extract DNA 2
Death before permission could be obtained 3
Other 3
Table 2
Demographic data and genotype frequencies of TNF and IL-10 polymorphisms in patients with sepsis and controls.
Patients (n = 224) Control individuals (n = 101)
Age 63.5 (49–72.75) 50 (46.5–55.5)
APACHE II 14 (9–19) -
SOFA (1)a 4 (2–9) -
-308 TNF-α promoter polymorphism
GG 186 (83) 82 (81.2)
GA 35 (15.6) 15 (14.9)
AA 3 (1.4) 4 (3.9)
TNF-β (NcoI polymorphism)
GG 16 (7.1) 10 (9.9)
GA 69 (30.8) 34 (33.7)
AA 139 (62.5) 57 (56.4)
IL-10-1082
GG 33 (14.8) 15 (14.8)
GA 99 (44.2) 50 (49.5)
AA 92 (41) 36 (35.7)
Values are expressed as median (25th to 75th percentile) or as n (%).aSOFA (1) means SOFA score of the first 24 hours in the hospital. 
APACHE, Acute Physiology and Chronic Health Evaluation score; SOFA, Sequential Organ Failure Assessment; TNF, tumour necrosis factor.Available online http://ccforum.com/content/10/4/R111
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septic shock in 61 (27.2%). Twenty patients who were admit-
ted with sepsis developed severe sepsis or septic shock, and
37 patients with severe sepsis developed septic shock. There-
fore, 58 patients fulfilled only sepsis criteria, 52 patients pre-
sented with severe sepsis criteria and 114 patients presented
with septic shock. Only 10 patients received activated protein
C as part of their treatment.
All patients had clinical signs of infection but the causal micro-
organism could not be microbiologically documented in 66
patients (29.4%). Thirty-one patients presented with positive
blood culture and focus of infection, 25 were only bacterae-
mic, and in 102 only culture of material from the apparent
focus of infection was positive. Polymicrobial sepsis was diag-
nosed in 22 cases. Table 3 shows the micro-organisms iso-
lated in blood and the sites of infection.
Empirical antibiotic therapy was inadequate in 16 patients (in-
hospital mortality 75%). The reasons for inadequacy of antibi-
otic therapy were as follows: pathogen resistant to prescribed
antibiotic (eight cases), pathogen not covered by empirical
antibiotic therapy (four cases) and no antimicrobial adminis-
tered within the first 24 hours in the hospital (four cases). In
one case (bacteraemia of undetermined source caused by
Prevotella oris) the patient died before they received adequate
antimicrobial treatment.
Predictors of in-hospital mortality
A bivariate analysis of risk factors for in-hospital mortality is
reported in Table 4. The mortality rate was significantly higher
for females than for males. Neither microbiological documen-
tation of sepsis nor the presence of bacteraemia was related
to a worse outcome. Median delay of initiation of adequate
antibiotic therapy was significantly longer in nonsurvivors than
in survivors (the patient who died before receiving adequate
antimicrobial treatment was excluded from this analysis).
All genotype frequencies were in Hardy-Weinberg equilibrium.
There were no significant differences in genotype or allele fre-
quencies between survivors and nonsurvivors. A strong asso-
Table 3
Micro-organisms isolated in different sites of infections and bloodstream
Micro-organism Site of infection Blooda
Escherichia coli 54 (35.3) 27 (43.5)
Streptococcus pneumoniae 23 (15) 7 (11.3)
Streptococcus spp. 15 (9.8) 8 (5.2)
Klebsiella spp. 12 (7.8) 6 (9.7)
Proteus mirabilis 7 (4.6) 2 (3.2)
Legionella pneumophila 7 (4.6) -
Enterococcus spp. 6 (3.9) 1 (1.6)
Pseudomonas spp 5 (3.3) -
Staphylococcus aureus 4 (2.6) 4 (6.4)
Neisseria meningitidis 4 (2.6) 3 (4.8)
Bacteroides fragilis 4 (2.6) 2 (3.2)
Chlamydia pneumoniae 3 (1.9) -
Salmonella enteritidis 2 (1.3) 1 (1.6)
Mycoplasma pneumoniae 2 (1.3)
Prevotella oris 1 (1.6)
Aeromonas hydrophila 1 (1.6)
Enterobacter spp. 1 (0.65)
Nocardia asteroids 1 (0.65)
Staphylococcus spp. 1 (0.65)
Leptospira 1 (0.65)
Coxiella burnetii 1 (0.65)
Total 153 (100) 63 (100)
Values are expressed as n (%). aSix episodes of polymicrobial bacteraemia were detected.Critical Care    Vol 10 No 4    Garnacho-Montero et al.
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Table 4
Bivariate analysis of risk factors for in-hospital mortality
Factor Nonsurvivors (n = 52) Survivors (n = 172) RR (95% CI) P
Sex 0.46 (0.28–0.74) 0.007
Male 21 (40.4) 106 (61.6)
Female 31 (59.6) 66 (38.4)
Age (years)a 61.5 (47.2–71.7) 67 (56.5–75.7) 0.09
Hepatic cirrhosis 5 (9.6) 9 (5.2) 1.93 (0.48–6.75) 0.32
Immunosuppression 5 (9.6) 4 (2.3) 4.47 (0.91–23.25) 0.03
COPD 5 (9.6) 17 (9.9) 0.97 (0.27–2.93) 0.95
End-stage renal disease 5 (9.6) 7 (4.1) 2.51 (0.6–9.62) 0.15
Chronic cardiac failure 2 (3.8) 3 (1.7) 2.25 (0.18–20.16) 0.33
Diabetes mellitus 13 (25) 44 (25.6) 0.97 (0.45–2.09) 0.93
Noncured malignancy 8 (15.4) 4 (2.3) 1.92 (7.64–35.84) 0.001
Alcoholism 5(9.6) 18 (10.5) 0.91 (0.25–2.73) 0.86
Smoking habit 8 (15.4) 41 (23.8) 0.65 (0.33–1.29) 0.25
APACHE IIa 18.5 (14–23.75) 12 (8–17) <0.001
APACHE II admission ICUa,b 22.5 (18–26) 15.5 (10–19.75) <0.001
SOFA (1)a,c 6 (3–11) 3 (1–7) <0.001
SOFA admission ICUa,b 10.5 (6.75–14) 6 (3–9.25) <0.001
Bacteraemia 13 (25) 43 (25) 1 (0.46–2.16) 1
Site of infection
Urologic 4 (7.7) 30 (17.5) 0.39 (0.1–1.21)
Central nervous system 3 (5.7) 10 (5.8) 0.75 (0.13–2.84)
Other 0 (0) 4 (2.3) 0 (0–5.04)
Soft tissue 3 (5.8) 14 (8.1) 0.69 (0.12–2.63)
Abdomen 23 (44.2) 59 (34.3) 1.52 (0.77–2.99)
Unknown 4 (7.7) 5 (2.9) 2.78 (0.53–13.42)
Lung 15 (28.8) 50 (29.1) 0.67 (0.32–1.37)
Genotype
-308 TNF-α promoter polymorphism 1.28 (0.49–3.46) 0.59
GG 45 (86.5) 141 (82%)
GA/AA 7 (13.5) 31 (18)
TNF-β (NcoI polymorphism) 0.74 (0.37–1.5) 0.37
GG/GA 17 (33.7) 68 (39.6)
AA 35 (67.3) 104 (60.4)
IL-10-1082 0.7 (0.22–1.88) 0.42
GG 6 (11.6) 27 (15.7)
GA/AA 46 (88.4) 145 (84.3)
Genotype -308 TNF GA/AA, TNF-β 
AA, IL-10-1082 GG
0.92 (0.45–1.84) 0.8
Yes 18 (34.1) 63 (36.6)Available online http://ccforum.com/content/10/4/R111
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ciation was found between the TNF-α-308 and TNF-β (NcoI)
polymorphisms. For TNF-α-308, 186 patients were GG
homozygous and 135 of them (72.5%) were AA homozygous
for the TNF-β  NcoI polymorphism. In addition, we also
assessed the impact on the outcome of the combination
formed by GA/AA at position -308, AA homozygosity for TNF-
β ( NcoI polymorphism) and IL-10-1082 GG homozygosity,
because this genotype could be considered the worst of the
possibilities.
Twenty-seven episodes of nosocomial infection were diag-
nosed in 22 patients. Empirical antimicrobial therapy for the
episode of nosocomial infection was inadequate in seven
cases (26%). Mortality did not significantly differ between
patients with (8/14 [36.4%]) and without nosocomial infection
(44/158 [21.8%]; P = 0.12).
By multivariate logistic regression analysis, only two factors
were independently associated with in-hospital mortality:
APACHE II score (OR 1.18, 95% CI 1.04–1.35) and delayed
initiation of adequate antibiotic therapy (OR 1.09, 95% CI
1.04–1.14).
Predictors of 90-day mortality
Only 222 patients could be evaluated for 90-day mortality.
Mortality rate was 25.7%. Multivariate analysis of risk factors
for 90-day mortality was identical to the analysis of in-hospital
mortality, with small differences in the OR.
Patients with septic shock
We also explored the impact of analyzed factors and con-
founding variables on mortality in 114 patients with septic
shock. Microbiological documentation of sepsis was achieved
in 85 patients (74.6%). Bivariate analysis of risk factors for in-
hospital mortality is reported in Table 5. No significant differ-
ences in genotype distribution or allele frequencies were
found between survivors and nonsurvivors. The genotype
formed by the combination of the allele A at position -308, AA
homozygosity for TNF-β (NcoI Ncolpolymorphism) and IL-10-
1082 GG homozygosity was not associated with a greater in-
hospital mortality.
Twenty-two episodes of nosocomial infection were diagnosed
in 18 patients (inadequate empirical antimicrobial therapy in
five cases). Mortality rate was not statistically different in
patients with or without nosocomial infection (50% versus
41.6%). Multivariate analysis confirmed that delayed adequate
antibiotic therapy was the only independent predictor of in-
hospital mortality (OR 1.06, 95% CI 1.01–1.10).
Impairment in inflammatory response
The risk for impairment in the inflammatory condition was eval-
uated by comparing those 57 patients who exhibited a deteri-
oration in inflammatory status (20 patients admitted with
sepsis developed severe sepsis or septic shock and 37
patients with severe sepsis developed septic shock) with
those 162 in whom the inflammatory response did not
progress (61 patients were admitted to the hospital with the
diagnosis of septic shock and were excluded from this analy-
sis). The rate of impairment in inflammatory response was sig-
nificantly greater in patients with inadequate empirical
antibiotic therapy than in patients with adequate empirical anti-
biotic therapy (13/16 versus 34/142; P < 0.001). Bivariate
analysis of risk factors for impairment in the inflammatory
response is shown in Table 6. Multivariate analysis identified
three variables independently associated with impairment of
the inflammatory response: APACHE II score (OR 1.17, 95%
CI 1.05–1.29), positive blood culture (OR 2.8, 95% CI 1.05–
7.7), and delayed initiation of adequate antibiotic therapy (OR
1.14, 95% CI 1.06–1.24).
SOFA score increased in 111 patients (median increase in
score 3 [range 1–6]). This increase was significantly greater in
nonsurvivors (5 [2–8.75]) than in survivors (0 [0–1.75]; P <
0001). All patients with inadequate empirical antibiotic ther-
apy within the first 24 hours of admission exhibited an increase
in SOFA score.
No 34 (65.4) 109 (63.4)
Empirical antibiotic therapy <0.001
Adequate 24 (46.1) 118 (68.6) 0.39 (0.20–0.77)
Inadequate 12 (23.1) 4 (2.3) 12.6 (3.53–55.57)
Not evaluable 16 (30.8) 50 (29.1) 1.08 (0.52–2.24)
Delayed surgical interventiona,d 16 (7–36) 12.5 (8–24) 0.77
Delayed of AATa 7 (4–28) 5 (3–10) 0.008
Unless otherwise stated, values are expressed as n (%). aResults expressed as median (25th to 75th percentiles). bOnly 178 patients were 
admitted to the ICU. c SOFA (1) means SOFA score in the first 24 hours in the hospital. dOnly in 'surgical patients' (n = 93). AAT, appropriate 
antibiotic therapy; APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; COPD, chronic obstructive pulmonary 
disease; ICU, intensive care unit; RR, relative risk; SOFA, Sequential Organ Failure Assessment.
Table 4 (Continued)
Bivariate analysis of risk factors for in-hospital mortalityCritical Care    Vol 10 No 4    Garnacho-Montero et al.
Page 8 of 12
(page number not for citation purposes)
Delta-SOFA correlated significantly with delayed initiation of
adequate antibiotic therapy (P < 0.0001; Figure 1). By multi-
ple linear regression, the only independent predictor of an
increase in SOFA score was delayed initiation of adequate
antibiotic therapy (P < 0.05).
Discussion
The major finding of the present study is the importance of
prompt and adequate antibiotic therapy on admission to hos-
pital in patients with sepsis. Timely adequate antibiotic admin-
istration is associated with decreased mortality and a
reduction in the impairment of inflammatory response,
whereas there are no strong associations between selected
TNF and IL-10 polymorphisms and outcomes.
The main purpose of identifying factors independently associ-
ated with mortality among septic patients is to recognize those
variables associated with high risk for death. From a practical
Table 5
Bivariate analysis of risk factors for in-hospital mortality in patients with septic shock
Factor Nonsurvivors (n = 49) Survivors (n = 65) RR (95% CI) P
Sex 0.07
Male 18 (36.7) 35 (43.9)
Female 31 (63.3) 30 (46.1)
Age (years)a 62.5 (55–75) 60 (45–72) 0.11
Hepatic cirrhosis 5 (10.2) 4 (6.2) 1.73 (0.35–9.21) 0.32
Immunosuppression 4 (8.2) 2 (3.1) 2.8 (0.38–31.92) 0.21
COPD 5 (10.2) 5 (7.7) 1.36 (0.29–6.30) 0.42
End-stage renal disease 5 (10.2) 3 (4.6) 2.35 (0.43–15.79) 0.21
Chronic cardiac failure 2 (4.1) 2 (3.1) 1.34 (0.09–19.07) 0.58
Diabetes mellitus 13 (26.5) 18 (27.7) 0.94 (0.38–2.35) 0.89
Noncured malignancy 6 (12.2) 1 (1.5) 8.9 (1.01–417) 0.24
Alcoholism 5 (10.2) 6 (9.2) 1.12 (0.25–4.71) 0.55
Smoking habit 8 (16.4) 10 15.4) 1.07 (0.35–3.29) 0.89
APACHE IIa 18 (14–22) 17 (13–21) 0.09
SOFA (1)a,b 6.5 (3–11) 8 (3–11) 0.8
Bacteraemia 13 (26.5) 26 (40) 0.54 (0.22–1.30) 0.2
Genotype
-308 TNF-α promoter polymorphism 1.80 (0.61–5.43) 0.42
GG 42 (85.7) 50 (77)
GA/AA 7 (14.3) 15 (23)
TNF-β (NcoI polymorphism) 0.66 (0.26–1.39) 0.19
GG/GA 16 (32.6) 29 (44.6)
AA 33 (67.4) 36 (55.4)
IL-10-1082 0.62 (0.18–1.96) 0.89
GG 6 (12.2) 12
GA/AA 43 (81.8) 53
Genotype TNF -308 GA/AA, TNF-β AA, 
IL-10-1082 GG
1.09 (0.46–2.61) 0.65
Yes 16 (32.6) 20
No 33 (67.4) 45
Delayed AATa 7.5 (4–28.5) 5.5 (3–12) 0.03
Unless otherwise stated, values are expressed as n (%). aResults expressed as median (25th to 75th percentiles). bSOFA (1) means SOFA score 
of the first 24 hours in the hospital. AAT, appropriate antibiotic therapy; APACHE, Acute Physiology and Chronic Health Evaluation; CI, 
confidence interval; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; RR, relative risk; SOFA, Sequential Organ Failure 
Assessment.Available online http://ccforum.com/content/10/4/R111
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Table 6
Bivariate analysis of risk factors for impairment of the inflammatory response
Factor Impairment of the inflammatory response P
Yes (n = 57) No (n = 106) RR (95%CI)
Sex 0.39 (0.19–0.79) 0.004
Male 25 (46.3) 71 (67)
Female 32 (53.7) 35 (33)
Agea 60 (50–72) 61 (48–70.2) 0.5
Hepatic cirrhosis 8 (14) 3 (2.8) 5.61 (1.26–33.83) 0.01
Immunosuppression 3 (5.3) 3 (2.8) 1.91 (0.25–14.67) 0.42
COPD 3 (5.3) 12 (11.3) 0.44 (0.1–1.72) 0.2
End-stage renal disease 3 (5.3) 4 (3.8) 1.42 (0.2–8.7) 0.7
Chronic cardiac failure 2 (3.5) 1 (0.94) 3.82 (0.2–227) 0.28
Diabetes mellitus 12 (21) 26 (24.5) 0.82 (0.35–1.9) 0.61
Noncured malignancy 4 (7) 4 (3.8) 1.92 (0.34–10.7) 0.71
Alcoholism 7 (12.3) 12 (11.3) 1.21 (0.4–3.58) 0.85
Smoking habit 10 (17.5) 30 (28.3) 0.22 (0.54–1.28) 0.12
APACHE IIa 14 (10–16.5) 10 (6–14) <0.0001
SOFA (1)a,b 3 (2–6) 2 (1–4) 0.003
Bacteraemia 18 (31.6) 14 (13.2) 3.03 (1.28–7.22) 0.005
Genotype
-308 TNF-α promoter polymorphism 0.88 (0.33–2.37) 0.77
GG 48 (84.2) 91 (85.8)
GA/AA 9 (15.8) 15 (14.2)
TNF-β (NcoI polymorphism) 1.25 (0.61–2.54) 0.5
GG/GA 24 (42.1) 39 (28.3)
AA 33 (57.9) 67 (63.2)
IL-10-1082 1.09 (0.46–2.61) 0.8
GG 8 (14) 15 (14.2)
GA/AA 49 (86) 91 (85.8)
Genotype -308 TNF GA/AA, TNF-β AA, 
IL-10-1082 GG
1.48 (0.71–3.09) 0.26
Yes 18 (31.5) 43 (40.6)
No 39 (68.5) 63 (59.4)
Delayed AATa 10 (6–25) 5 (2.5–8) <0.001
Unless otherwise stated, values are expressed as n (%). aResults expressed as median (25th to 75th percentiles). bSOFA (1) means SOFA score 
of the first 24 hours in the hospital. AAT, appropriate antibiotic therapy; APACHE, Acute Physiology and Chronic Health Evaluation; CI, 
confidence interval; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; RR, relative risk; SOFA, Sequential Organ Failure 
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point of view, identified factors should be modifiable with med-
ical interventions or be incorporated into our therapeutic arse-
nal if they are to achieve a reduction in mortality. The impact on
outcome of early antibiotic treatment has been demonstrated
for infections such as community-acquired pneumonia [22],
although in patients with community-acquired meningitis there
was a trend only in those who were less severely ill [23]. Inter-
estingly, the impact of early adequate antibiotic therapy in
patients with sepsis has never been assessed.
By multivariate analysis, we found that the risk for in-hospital
mortality increased by 9% for every hour of delay to adminis-
tration of the correct antibiotic regimen. Moreover, in patients
with septic shock, the only independent predictor of in-hospi-
tal mortality was delayed administration of adequate antibiotic
therapy. This finding is of great importance because septic
shock is associated with high mortality rates, and the associa-
tion of septic shock with death persists after adjusting for
prognostic factors such as organ failure [2]. Valles and cow-
orkers [4] found that inadequate antibiotic therapy was the
most important determinant of survival in bacteraemic
patients, and this finding was even more marked in patients
with septic shock.
In the present study, mortality rates of septic patients with and
without nosocomial infection were similar, although the inci-
dence of sepsis in our study was lower than that in other series
[24]. It should not be overlooked that one-fifth of our patients
were not admitted to the ICU, we only noted severe nosoco-
mial infections (urinary and wound infections were not noted),
and community-acquired infection is a protective factor with
respect to nosocomial infection in the ICU [25]. In any case,
the impact on outcome of hospital-acquired infection seems
not to be crucial in patients with sepsis at admission, and mor-
tality is more directly related to the severity of illness and the
initial management.
Approximately half of the patients presenting with sepsis dete-
riorated to a more severe stage in the inflammatory response
during subsequent days [26]. In a recent multicentre study,
Alberti and coworkers [27] proposed a score to forecast
which patients may present with a deteriorating clinical state.
In the present study, using two different approaches, delayed
initiation of adequate antibiotic therapy was an independent
predictor of impairment in inflammatory response. This is of the
utmost importance because the more severe the inflammatory
response, the greater the mortality rate.
Genetic variations within the TNF and IL-10 genes may influ-
ence mortality rates in patients with sepsis. Polymorphisms in
these genes may determine the concentrations of proinflam-
matory and anti-inflammatory cytokines, and may influence
whether patients have a marked hyper-inflammatory or anti-
inflammatory response to infection. A delicate balance
between inflammation and anti-inflammation is required if the
adverse effects associated with predominance of either state
is to be avoided. In sepsis, that elevated IL-10 serum levels
have been associated with poor outcome might be a result of
the development of immunoparalysis and increased risk for
multiple organ dysfunction syndrome [9].
Previous studies have yielded conflicting findings on the
impact on outcome of the two TNF polymorphisms in septic
patients. In the case of the -308 (G/A) polymorphism, the fre-
quency of TNF-2 (containing 'A') was higher among those sep-
tic shock patients who died, and this genotype was an
independent predictor of mortality on multivariate analysis
[10]. This association was also found by other investigators
[28], but others were unable to demonstrate an association
between this polymorphism and outcome in patients with sep-
sis [11]. Similar contradictory findings have been reported in
the case of TNF-β (NcoI polymorphism); mortality in severe
sepsis was higher in TNFB2 (AA) individuals [29,30], although
other investigations found no such association [31]. A recent
study enrolling 213 patients with severe sepsis [32] found no
association between these polymorphisms and mortality. In
our series, 72.5% of those who were GG homozygous for
TNF-α-308 were AA homozygous for TNF-β' polymorphism,
which is in agreement with a recent study that found these two
polymorphisms to be in strong linkage disequilibrium [33].
Two studies conducted in patients with community-acquired
pneumonia [34,35] found no association between the two
TNF polymorphisms or the IL-10-1082 polymorphism and risk
for developing septic shock or mortality. Moreover, patients
with invasive pneumococcal disease who were GG
homozygous for the IL-10-1082 polymorphism exhibited
greater risk for septic shock, whereas mortality was unaffected
Figure 1
Correlation between delta-SOFA and delayed initiation of adequate  antibiotic therapy Correlation between delta-SOFA and delayed initiation of adequate 
antibiotic therapy. SOFA, Sequential Organ Failure Assessment.Available online http://ccforum.com/content/10/4/R111
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[36]. In this study, the two TNF polymorphisms were not asso-
ciated with a worse evolution of disease.
There is currently extensive disagreement on the value of asso-
ciation studies for the detection of genetic variants that con-
tribute to death, especially in complex situations such as
sepsis. Diverse methodological pitfalls may account for many
contradictory results. Moreover, it must be acknowledged that
the biological role of many of these polymorphisms remains to
be elucidated. Thus, recent functional studies suggest that the
much studied 308 G/A polymorphism is not functional,
whereas the function of other TNF polymorphism remains con-
troversial [37].
We acknowledge several limitations of our study. First,
although a protocol following current recommendations for
treatment of sepsis and septic shock was used (intravenous
corticosteroids, continuous infusion of insulin and mechanical
ventilation with low tidal volumes), we did not control certain
variables that could have influenced outcomes, such as the
total amount of fluid infused in the first few hours [38]. Second,
the use of recombinant activated protein C in our study was
very restricted, although this is not unusual in clinical practice
[39]. Third, only three polymorphisms of two mediators were
evaluated. Given the vast number of mediators that have been
implicated in the response to an infectious agent, we cannot
exclude the possibility that other polymorphisms not geno-
typed in the present study or specific haplotypes could influ-
ence survival [40]. Finally, our study may be underpowered to
detect statistically significant differences, especially in septic
shock patients, given the small sample size.
Despite these limitations, the study is unique in that it included
an ethnically homogeneous population of patients admitted to
the hospital with a diagnosis of sepsis, and evaluated the pro-
gression of the syndrome and the factors associated with mor-
tality following their admission to the hospital. Among the
factors analyzed, all enrolled patients were genotyped for
three polymorphisms of two key mediators, following recent
recommendations for genetic association studies [41]. Our
findings emphasize that better use of conventional treatments
is necessary before sophisticated interventions should be
introduced into the clinical setting; we were unable to detect
strong associations between these three polymorphisms and
mortality in patients with sepsis at admission to hospital [42].
Conclusion
Physicians should strive to initiate adequate antibiotic therapy
as soon as possible in patients with sepsis. Clearly, surgical
removal of the septic focus remains at the foundation of suc-
cessful therapy, as is appropriate and prompt resuscitation of
patients with severe sepsis and septic shock. Findings relating
to the value of the association study, designed for detection of
genetic variants contributing to death in septic patients, have
been contradictory; this has resulted in increasing uncertainty
among investigators and care givers. Therefore, large genetic
studies are needed before genotypes can be incorporated into
patient-tailored therapy. In the meantime, all educational pro-
grammes designed to reduce mortality in sepsis should spe-
cifically promote the correct and early use of antibiotics in
different clinical settings.
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